Patent details
LUC00194 Product Name: avélumab
Basic Information
- Publication number:
- LUC00194
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP127904324
- Legal Status:
- Inactive
- Application number:
- LUC00194
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/17/1214
- Marketing Authorization Type:
- Marketing Authorization Date:
- 20/09/2017
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 24/12/2020
- First Marketing Authorization date:
- 20/09/2017
- Grant date:
- 14/12/2021
- Activation date:
- Publication date:
- 24/12/2020
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 20/09/2032
- SPC Extension Expiration:
- 20/09/2032
- Rejection date:
- Withdrawal date:
Owner
- From:
- 24/12/2020
- Name:
- Merck Patent GmbH
- Address:
- Frankfurter Strasse 250, 64293 Darmstadt, Germany (DE)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 24/12/2020
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2021/01
- Publication date:
- 05/01/2021
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
2
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2022/01
- Publication date:
- 03/01/2022
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
| Filing date | Document type | Number of pages |
|---|---|---|
| 24/12/2020 | Application Form | 4 |
| 24/12/2020 | MA publication | 10 |
| 24/12/2020 | Summary of the product caracteristics | 40 |
| 24/12/2020 | Marketing authorization | 3 |
| 24/12/2020 | Outgoing Correspondence | 1 |
| 24/12/2020 | Publication | 1 |
| 14/12/2021 | Publication | 1 |
| 14/12/2021 | Outgoing Correspondence | 1 |
| 14/12/2021 | Certificate | 1 |